Abstract:Importance The specific pattern/trajectory of β-amyloid (Aβ) pathology spreading in Alzheimer’s disease (AD), from default mode network (DMN) regions to sensory-motor areas, is well known, but poorly understood. Objective To determine if resting-state global brain activity is linked to early Aβ deposition in the DMN. Design This is a retrospect analysis of multi-modal and longitudinal data from the Alzheimer’s disease Neuroimaging Initiative (ADNI) cohort. Setting The ADNI was a multicenter project involving 63 research centers. Participants The study included 144 participants (72.6 ± 7.5 years; 73 females) of whom 28 were controls, 21 had significant memory concerns, 72 had cognitive impairment ( N =72), and 23 had AD. There were both baseline and 2-year follow-up data for Aβ-PET for 112 of the subjects. They were classified into following stages based on the CSF Aβ42 (CSF+: < 192 ng/L ) and cortical Aβ (PET+: > 0 . 872 SUVR ) levels: non-Aβ-accumulators (CSF-/PET-); early-Aβ-accumulators (CSF+/PET-); and late-Aβ-accumulators (CSF+/PET+). Exposure Resting-state brain activity was assessed by functional magnetic resonance imaging (rsfMRI), whereas glymphatic function was estimated by the coupling between fMRI blood-oxygen-level-dependent (BOLD) signals and CSF movements. Main Outcomes and Measures Cortical Aβ accumulation measured by [18][1]F-AV45 amyloid-positron emission tomography (PET), CSF Aβ42, and total and phosphorylated tau protein levels in all participants. Results Glymphatic function assessed by fMRI was strongly (ρ > 0.43, P < 0.042) associated with various markers of protein aggregation in early Aβ accumulators in whom Aβ just begins to accumulate cortically in the DMN. Among these early accumulators, the preferential Aβ accumulation in the DMN regions in the subsequent two years was correlated with lower gBOLD signal (ρ = 0.51, P = 0.027) and lower local glymphatic function (ρ = 0.48, P = 0.041) in the same regions at baseline. Conclusions and Relevance Resting-state global brain activity and related glymphatic function are linked to Aβ pathology, particularly its preferential deposition in the DMN at the earliest AD stages. This suggests potential novel early therapeutic directions that might provide disease modification. Question Why does the β-amyloid (Aβ) plaque deposit preferentially in the default mode network (DMN) regions at early preclinical stages of Alzheimer’s disease? Findings In this analytic observational cohort study with 144 subjects, we found that the preferential reduction of global resting-state brain activity in the DMN, as well as its coupling with cerebrospinal fluid movement, was significantly correlated with the preferential Aβ accumulation in these DMN regions among 19 subjects with early Aβ accumulation. Meaning Resting-state global brain activity plays a role in the early Aβ accumulation in the DMN, presumably due to its involvement in glymphatic clearance. ### Competing Interest Statement Richard B. Mailman: 1. Unrelated research funding: National Institutes of Health (R01 NS105471). 2. Unrelated: Holds patents related to D1 dopamine agonists as therapeutic agents (not being prosecuted). Past D1-related grant, consulting, and travel from Pfizer Central Research (none since 2017). Received travel expenses from Cerevel Therapeutics in 2019 and 2022. Consultant to Cerevel Therapeutics (2022-present). Past expert witness or consultant to several law firms and US Department of Justice. Past consultant to Jazz Pharma (publishing costs only). The Penn State College of Medicine actively manages Dr. Mailman's disclosed potential conflicts of interest. Xuemei Huang: 1. Unrelated research: Michael J. Fox Foundation for Parkinson's Research; Bristol Myers Squibb/Biogen; Pfizer. 2. Unrelated: Has interest in patents related to D1 technology that are not being actively prosecuted; this conflict of interest has been disclosed to, and managed by, the Penn State University. * Aβ : β-amyloid AD : Alzheimer’s disease ADNI : Alzheimer’s Disease Neuroimaging Initiative APOE : apolipoprotein E AQP4 : astroglial aquaporin-4 BOLD : blood-oxygen-level-dependent CSF : cerebrospinal fluid DMN : default mode network EPI : echo-planar image FC : functional connectivity FPN : frontoparietal network FWHM : full width at half maximum gBOLD : global BOLD IIH : Idiopathic intracranial hypertension MCI : mild cognitive impairment MNI-152 : 152-brain Montreal Neurological Institute MRI : Magnetic resonance imaging PD : Parkinson’s disease PET : positron emission tomography PG : principal gradient P-tau : phosphorylated tau rBOLD : regional BOLD rsfMRI : resting-state fMRI SM : somatosensory SMC : significant memory concern SUVR : Standardized uptake value ratio T-tau : total tau TE : echo time TR : repetition time [1]: #ref-18

Resting FDG-PET in neurologically normal individuals reporting dream enactment behavior: Preclinical dementia with lewy bodies?

A preliminary fluorodeoxyglucose positron emission tomography study in healthy adults reporting dream-enactment behavior.

18F-Fluorodeoxyglucose Positron Emission Tomography in Dementia with Lewy Bodies.

Assessing Cerebral Glucose Metabolism in Patients with Idiopathic Rapid Eye Movement Sleep Behavior Disorder

O1‐04‐05: PATHOLOGIC ASSOCIATIONS OF FDG PET IN LEWY BODY DISEASE

Cognitive Impact of β‐Amyloid Load in the Rapid Eye Movement Sleep Behavior Disorder–Lewy Body Disease Continuum

Early β-amyloid accumulation and hypoconnectivity in the default mode network are related to its disengagement from global brain activity

Wider and Faster Degeneration of White Matter in Parkinson’s Disease with Possible REM Sleep Behaviour Disorder

99m Tc-HMPAO SPECT Perfusion Signatures Associated With Clinical Progression in Patients With Isolated REM Sleep Behavior Disorder

Characterizing the Heterogeneous Metabolic Progression in Idiopathic REM Sleep Behavior Disorder.

Deep learning signature of brain [18F]FDG PET associated with cognitive outcome of rapid eye movement sleep behavior disorder

Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study

The impact of probable rapid eye movement sleep behavior disorder on Parkinson's disease: A dual-tracer PET imaging study

CSF markers of neurodegeneration Alzheimer's and Lewy body pathology in isolated REM sleep behavior disorder

Glucose Metabolic Brain Network Differences Between Chinese Patients with Lewy Body Dementia and Healthy Control

Prediction of later clinical course by a specific glucose metabolic pattern in non-demented patients with probable REM sleep behavior disorder admitted to a memory clinic: A case study

Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy

Clinico-imaging features of subjects at risk of Lewy body disease in NaT-PROBE baseline analysis

Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder

Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies

Brain MRI Biomarkers in Isolated Rapid Eye Movement Sleep Behavior Disorder: Where Are We? A Systematic Review